Phase 2 N=87 IN Sub-Dissociative Ketamine vs IN Fentanyl
Bone Fracture
Primary: Primary Outcome: Number of Participants With Minor Side Effects and Significant Adverse Events — 0; 0; 41; 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
Cannabis Use
Primary: Cannabis Self-administration — 5.75; 9.2; 5.75; 7.5 puffs of cannabis chosen
Phase 2 N=138 PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Carcinoma, Basal Cell
Primary: Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR) — 22.2; 32.1 Percentage of Participants
Phase 2 N=16 Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia
Post-bariatric Hypoglycemia
Primary: Number of Participants With Meal-provoked Hypoglycemia, Defined as Sensor Glucose <65 mg/dL — 1; 5 participants — p=0.103
Phase 2 N=2,252 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
COVID-19
Primary: Pooled Analysis (Phase 3 [Cohort 1] and Phase 2 [Cohort 1A]): Time-weighted Average (TWA) Change in Viral Load in Nasopharyngeal (NP) Samples Based on Seronegative mFAS…
Phase 2 N=40 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
COPD
Primary: Part A: Pharmacokinetic Parameter AUC0-12 — 175; 611; 1550; 5860 h*pg/mL
Phase 2 N=63 A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer · Urothelial Carcinoma · Urothelial Carcinoma Bladder
Primary: Complete Response (CR) Rate for UGN-102 Treatment — 65.1 percentage of patients
Phase 2 N=98 Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Follicular Lymphoma
Primary: Complete Response Rate (CRR) Per Independent Review Committee (IRC) Assessment — 69.1 Percentage of participants
Phase 2 N=49 Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Pancreatic Cancer
Primary: Progression-free Survival — 9.2; 8.9 months
Phase 2 N=22 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Ewing's Sarcoma
Primary: Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations — 5; 6; 9 Participants
Phase 2 N=10 Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Severe Combined Immunodeficiency Due to ADA Deficiency
Primary: Percentage of Participants With Treatment Efficacy After Treatment With OTL 101 (6 Months) — 100; 100; 90 percentage of participants
Phase 2 N=317 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Total Mayo Score at Week 8 (Induction Period) — 7.88; 5.85; 4.00; 3.27 Units on a scale — p=0.0017
Phase 2 N=328 A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
Endometriosis
Primary: Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS) — 34.5; 49.4; 61.5; 56.4 percentage of subjects
Phase 2 N=12 Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Primary: Phase I - Dose-Limiting Toxicity — 0; 0 dose-limiting toxicities
Phase 2 N=36 p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants